N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Primary: Objective Response Rate — 0 Participants
Phase 2 N=33 FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-Free Survival — 14 Participants
Phase 3 N=350 Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Axillary Hyperhidrosis
Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…
N/A N=20 Measuring Hydrogen Peroxide in Exhaled Breath Condensate in HV
Proof Of Concept Study
Primary: Hydrogen Peroxide in Exhaled Breath Condensate — 0.101 µM
N/A N=119 A Trial of an Adolescent Male Sexual Health Intervention
Contraception Behavior
Primary: Number of Eligible Participants Who Agreed to be Enrolled in the Study — 119 participants
Phase 4 N=15 Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
Healthy Lactating Women
Primary: AUCtau,Milk — 21.4; 1.59 µg•h/mL, (CV%)
N/A N=134 TrueRelief Efficacy for Post-cesarean Pain (ELECTRON)
Post-cesarean Pain
Primary: Median of Total Inpatient Oral Opioids Consumption (in Morphine Milligram Equivalents) in Treatment With TrueRelief Device Versus Sham Comparator Groups. — 19.75; 37.50…
Phase 3 N=568 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. — 14.2; 15.6 ETDRS Letters — p=.0004
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
Phase 1 N=14 Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Metastatic Melanoma
Primary: Percentage of Patients With Adverse Events (AEs) — 5; 4; 1; 0 Participants
N/A N=25 Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL)
Autism Spectrum Disorder
Primary: Change in Autism Symptoms — -6.77 units on a scale — p=<0.05
N/A N=197 Self-Management in Parents of Technology-Dependent Children
Caregivers · Parents · Self-Management
Primary: Psychological Outcome- Health Related Quality of Life — 40.5; 37.0; 41.9; 39.70 score on a scale — p=<0.05
Phase 1 N=54 Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
Hypertension
Primary: Change in Daytime Systolic Blood Pressure — 5.19; -2.71; -0.48 mmHg